How can anyone say that at this point? Basically you set up high expectation you can't possibly meet in the future.
Here is a good summary of ALK inhibitor from ASCO presentations. LDK378 ORR has come down for both Xalkori naive and resistant with larger sample size. However, CH5424802 in 46 Xalkori-naïve Japanese patients, CH5424802 achieved an unprecedented ORR of 93.5% and median duration of response exceeding 14 months: